FY2025 Earnings Estimate for NRXP Issued By HC Wainwright

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright upped their FY2025 earnings estimates for shares of NRx Pharmaceuticals in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst V. Bernardino now forecasts that the company will earn ($0.06) per share for the year, up from their previous estimate of ($0.07). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.75) per share.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.10).

A number of other brokerages have also issued reports on NRXP. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a report on Monday, December 2nd. D. Boral Capital reissued a “buy” rating and issued a $31.00 price target on shares of NRx Pharmaceuticals in a research note on Monday.

NRx Pharmaceuticals Stock Down 2.9 %

Shares of NRXP opened at $2.01 on Monday. NRx Pharmaceuticals has a 52-week low of $1.10 and a 52-week high of $6.01. The stock has a fifty day simple moving average of $2.70 and a two-hundred day simple moving average of $2.04. The company has a market capitalization of $34.00 million, a PE ratio of -0.94 and a beta of 1.22.

Hedge Funds Weigh In On NRx Pharmaceuticals

A number of hedge funds have recently modified their holdings of the business. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals in the fourth quarter valued at about $56,000. Millennium Management LLC acquired a new position in shares of NRx Pharmaceuticals in the 4th quarter worth approximately $61,000. Anson Funds Management LP lifted its holdings in shares of NRx Pharmaceuticals by 30.3% in the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock worth $408,000 after acquiring an additional 43,135 shares during the last quarter. AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after purchasing an additional 180,229 shares during the period. Finally, Sassicaia Capital Advisers LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter valued at approximately $33,000. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.